Trial reportPsychological medicine2026
Selective enhancement of cost sensitivity by methylphenidate in adult ADHD: a randomized placebo-controlled trial.
Trial report in Psychological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAttention-deficit hyperactivity disorder (ADHD) is associated with impairments in real-life decisions, many involving balancing costs and benefits. Increasing dopamine and norepinephrine with stimulant medication improves decision-making in ADHD. However, it is unclear whether stimulant medication affects sensitivity to costs and/or benefits or alters the speed-accuracy tradeoff. Here, we applied the drift diffusion model (DDM) to assess how the stimulant medication methylphenidate (MPH) affects subprocesses of cost-benefit decision-making in ADHD.
methodsSixty-one adult participants with ADHD and 63 healthy controls completed a cost-benefit decision-making task in a randomized double-blind placebo-controlled design. ADHD participants were tested once on and once off MPH. Control participants performed the task in two sessions without medication. The task entailed deciding whether to accept or reject a stimulus based on learned cost and benefit value associations. The effect of ADHD and medication on subprocesses of decision-making was disentangled by estimating task performance with DDM parameters drift rate, starting point bias, and decision threshold, representing evidence accumulation, a priori accept/reject bias, and the speed-accuracy tradeoff, respectively. Primary analyses used a modified intention-to-treat sample, including participants with main-phase data from both sessions.
resultsThe DDM analysis identified impaired evidence accumulation combined with premature responding in participants with ADHD, indicated by reduced sensitivity to costs and benefits and narrower decision thresholds. MPH altered the cost-benefit balance by improving sensitivity to costs. Lastly, lower cost sensitivity was associated with greater symptom severity and higher prescribed dosage in ADHD.
conclusionsMethylphenidate alters cost-benefit decision-making in ADHD by increasing sensitivity to costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.